Table 1.
Weight loss after bariatric artery embolization in prospective or RC trials.
|
| ||||||||
|---|---|---|---|---|---|---|---|---|
| FIRST AUTHOR[REFERENCE] | YEAR | DESIGN | BASELINE BMI | AGE, Y | N° PATIENTS | FOLLOW-UP, MONTH | ABSOLUTE WEIGHT LOSS, KG | MEAN WEIGHT LOSS, % |
|
| ||||||||
| Kipshidze [20] | 2015 | prospective | 42.2 ± 6.8 | 44.7 ± 7.4 | 5 | 20–24 | 22.4 ± 4,2 | 17.19 |
|
| ||||||||
| Syed [21] | 2016 | prospective | 42.4 ± 2.5 | 41.0 ± 10,7 | 4 | 6 | 9.19 ± 6.0 | 8.52 |
|
| ||||||||
| Bai [23] | 2017 | prospective | 38.1 ± 3.8 | 42.8 ± 13.9 | 5 | 9 | 12.90 ± 14.7 | 12.64 |
|
| ||||||||
| Weiss [18] | 2019 | prospective | 45 ± 4.1 | 44 ± 11 | 20 | 12 | 7.62 | 11.5 |
|
| ||||||||
| Elens [2] | 2019 | prospective | 28.9 ± 2.5 | 38 ± 10 | 11 | 6 | 8.00 ± 5.1 | 10.00 |
|
| ||||||||
| Zaitoun [26] | 2019 | prospective | 37.4 ± 3.3 | 37.5 ± 8.8 | 10 | 6 | 8.24 ± 3.1 | 8.90 |
|
| ||||||||
| Reddy [25] | 2020 | RCT | 39.6 ± 3.8 | 45.5 ± 9.8 | 20 | 24 | NA | 9.00 |
|
| ||||||||
| Pirlet [24] | 2020 | prospective | 49.4 (IQR 43.2–61.7) | NA | 7 | 24 | 11 (IQR 4.25–21.5) | 7.7 (IQR 3.2–14.1) |
|
| ||||||||
| Levigard [27] | 2021 | prospective | 36.4 ± 2.6 | 37.5 ± 7.3 | 10 | 6 | 6.22 ± 3.6 | 6.8 |
|
| ||||||||
Age, baseline BMI are reported as mean ± SD (standard deviation) or mean (IQR (interquartile ranges)).
BMI: body mass index; NA: not available; RCT: randomized controlled trial.